Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility

Recent Milestones Aim to Bring a New Category of Care to One of Veterinary Medicine's Largest Unmet Needs Gallant granted eligibility for expanded conditional approval by FDA-CVM for canine osteoarthritis (OA) stem cell therapy; targeting conditional approval in 2028. Randomized, blinded,...